Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück zu finanzen.net geht es hier.
SMI 10’739 -0.7%  SPI 13’819 -0.8%  Dow 30’947 -1.6%  DAX 13’034 -1.5%  Euro 1.0006 -0.7%  EStoxx50 3’517 -0.9%  Gold 1’827 0.4%  Bitcoin 19’129 -1.4%  Dollar 0.9513 -0.6%  Öl 119.3 1.0% 
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
09.05.2022 12:15:37

BioNTech earnings jump after 750 million COVID vaccines invoiced

BioNTech , the U.S-listed German biotech, said its first-quarter profit more than tripled to €3.7 billion ($3.9 billion), or €14.24 per share, from €1.13 billion, or €4.39 per share, as revenue jumped to €6.38 billion from €2.05 billion, mostly on its share of COVID-19 vaccine sales from Pfizer and Fosun Pharma as well as direct sales to customers in Germany and Turkey. Analysts polled by FactSet had expected earnings of €9.70 per share on sales of €4.59 billion. In the first quarter of 2022, BioNTech and Pfizer have invoiced approximately 750 million COVID-19 vaccine doses. It reiterated its 2022 targets that include between €13 billion and €17 billion in COVID-19 vaccine revenue. BioNTech shares edged up 2% in premarket trade but have dropped 47% this year.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Weiter zum vollständigen Artikel bei "Market Watch"

BITCOIN KURSZIEL 100'000 US-DOLLAR? WELCHER COIN KÖNNTE DER NÄCHSTE VERDOPPLER SEIN?

Informieren Sie sich aus erster Hand über Nachrichten, die Krypto-Kurse bewegen. Abonnieren Sie jetzt kostenlos unseren neuen Krypto-Newsletter!